BB Healthcare Trust PLC Issue of Equity (0945R)
March 03 2021 - 11:47AM
UK Regulatory
TIDMBBH
RNS Number : 0945R
BB Healthcare Trust PLC
03 March 2021
3 March 2021
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY,
TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA,
JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE OF DOUBT,
THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL, RESIDENT OR CITIZEN
OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY
MEMBER STATE OF THE EEA (FOR THE AVOIDANCE OF DOUBT, THIS DOES NOT
INCLUDE THE UK)
BB Healthcare Trust plc
Issue of Ordinary Shares
BB Healthcare Trust plc (the "Company") announces that it has today
issued 250,000 of its ordinary shares of one penny each ("Ordinary
Shares") pursuant to its block listing facility. The Ordinary Shares
will be issued at a price of 186.08 pence per Ordinary Share, a
premium to the prevailing net asset value ("cum income") per Ordinary
Share.
Following the issue of Ordinary Shares, the Company's issued share
capital will comprise (510,045,455) Ordinary Shares and this is
the total number of Ordinary Shares with voting rights in the Company.
This figure (510,045,455) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required
to notify their interest in, or a change to, their interest in the
Company under the Financial Conduct Authority's Disclosure Guidance
and Transparency Rules.
The Company's LEI is: 213800HQ3J3H9YF2UI82
For further information please contact:
Bellevue Asset Management (UK) Ltd.
Mark Ghahramani
Telephone: +44 (0) 203 326 2981
J.P. Morgan Cazenove
James Bouverat (Sales)
Telephone: +44 (0) 207 134 2224
Alvarium Securities Limited
Mark Thompson +44 (0)20 7016 6711
Eddie Nissen +44 (0)20 7016 6713
Oliver Kenyon +44 (0)20 7195 1448
Disclaimer
This announcement does not constitute a prospectus relating to the
Company and does not constitute, or form part of, any offer or invitation
to sell or issue, or any solicitation of any offer to purchase or
subscribe for, any shares in the Company in any jurisdiction nor
shall it, or any part of it, or the fact of its distribution, form
the basis of, or be relied on in connection with or act as any inducement
to enter into, any contract therefore.
J.P. Morgan Cazenove and Alvarium Securities Limited, which are
authorised and regulated by the Financial Conduct Authority, are
acting for the Company only in connection with the matters described
in this announcement and are not acting for or advising any other
person, or treating any other person as their client, in relation
thereto and will not be responsible for providing the regulatory
protection afforded to clients of Alvarium Securities Limited and
J.P. Morgan Cazenove or advice to any other person in relation to
the matters contained herein.
The shares of the Company have not been and will not be registered
under the US Securities Act of 1933, and may not be offered or sold
in the United States absent registration or an applicable exemption
from the registration requirements. Moreover, the shares of the
Company have not been, nor will they be, registered under the applicable
securities laws of Australia, Canada, the Republic of South Africa,
Japan or any member state of the EEA (other than the United Kingdom).
Further, the Company will not be registered under the US Investment
Company Act of 1940, as amended. Subject to certain exceptions,
the shares of the Company may not be offered or sold in the United
States, Australia, Canada, the Republic of South Africa, Japan or
any member state of the EEA (other than the United Kingdom or to
professional investors in Ireland) or to, or for the account or
benefit of, any national, resident or citizen of the United States,
Australia, Canada, the Republic of South Africa, Japan or any member
state of the EEA (other than the United Kingdom or to professional
investors in Ireland). The share issuance programme, and the distribution
of this announcement, in other jurisdictions may be restricted by
law and the persons into whose possession this announcement comes
should inform themselves about, and observe, any such restrictions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFLFSDVRIVIIL
(END) Dow Jones Newswires
March 03, 2021 12:47 ET (17:47 GMT)
Bellevue Healthcare (LSE:BBH)
Historical Stock Chart
From Apr 2024 to May 2024
Bellevue Healthcare (LSE:BBH)
Historical Stock Chart
From May 2023 to May 2024